Automatically clustered newsroom coverage around one of the most active themes in the intellectual property ecosystem.
On August 3, 2026, Decoy Therapeutics announced a significant expansion of its intellectual property portfolio, now encompassing seven patent families with 19 pending applications across the U.S., Australia, Canada, China, Europe, Japan, and New Zealand. The portfolio protects its Designable Multi-Antivirals (D-MAVs™)…
Decoy Therapeutics Inc. has expanded its intellectual property holdings to encompass seven patent families and 19 pending applications worldwide. The portfolio safeguards antiviral peptide conjugates, manufacturing methods, formulations, and the IMP³ACT™ design platform that underpins its Designable Multi-Antivirals (…
Vector Science & Therapeutics Corp. has expanded its intellectual property holdings to include 15 patent applications filed over the past two years. These applications cover a wide array of technologies aimed at enhancing precision delivery of therapeutic agents, particularly peptides and biologics, via non-invasive,…
Subscribe to receive daily and weekly newsroom coverage aligned to this trend cluster and adjacent IP developments.